Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective

Kanhai, A.A.; Bange, H.; Verburg, L.; Dijkstra, K.L.; Price, L.S.; Peters, D.J.M.; Leonhard, W.N. (2020)

Article / Letter to editor

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common monogenic disorders, characterized by the progressive formation of fluid-filled cysts. Tolvaptan is an approved drug for ADPKD patients, but is also associated with multiple side effects. The peroxisome proliferator-activator receptor gamma (PPAR gamma) agonist pioglitazone slows disease progression in the PCK rat model for PKD. Here, we tested whether a combination treatment of relevant doses of tolvaptan and pioglitazone leads to improved efficacy in an adult-onset PKD mouse model. Tolvaptan indeed slowed PKD progression, but the combination treatment was not more effective than tolvaptan alone. In addition, although pioglitazone raised plasma levels of its surrogate drug marker adiponectin, the drug unexpectedly failed to slow PKD progression. The pioglitazone target PPAR. was expressed at surprisingly low levels in mouse, rat and human kidneys. Other pioglitazone targets were more abundantly expressed, but this pattern was comparable across various species. The data suggest that several potential pharmacokinetic and pharmacodynamic (PK/PD) differences between different species may underlie whether or not pioglitazone is able to slow PKD progression. The ongoing phase II clinical trial with low-dose pioglitazone treatment (NCT02697617) will show whether pioglitazone is a suitable drug candidate for ADPKD treatment.

• All authors: Kanhai, A.A.; Bange, H.; Verburg, L.; Dijkstra, K.L.; Price, L.S.; Peters, D.J.M.; Leonhard, W.N.
• Date: 2020-02-03
• Journal: Scientific Reports
• Volume: 10
• Issue: 1
• DOI: doi:10.1038/s41598-020-58382-z
• Link: https://www.nature.com/articles/s41598-020-58382-z